How Will AbbVie (ABBV) Stock React To Its Second Quarter Earnings Beat?

NEW YORK (TheStreet) -- AbbVie (ABBV) reported second quarter EPS of 82 cents per diluted share, beating analysts earnings expectations by 6 cents per share.

Second quarter revenue rose 5.1% over the same period last year to $4.93 billion, beating analysts guidance of $4.7 billion.

AbbVie shares are flat in early market trading today.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

TheStreet Ratings team rates ABBVIE INC as a Hold with a ratings score of C. TheStreet Ratings Team has this to say about their recommendation:

"We rate ABBVIE INC (ABBV) a HOLD. The primary factors that have impacted our rating are mixed - some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its notable return on equity, revenue growth and increase in net income. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and weak operating cash flow."

ABBV ChartABBV data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

The Hottest Investing Plays in the Booming Weed Industry for 2018

The Hottest Investing Plays in the Booming Weed Industry for 2018

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

AbbVie Appears Ready to Start a New Advance at Any Time

AbbVie Appears Ready to Start a New Advance at Any Time

Watch These Biotechs and the FDA Calendar

Watch These Biotechs and the FDA Calendar

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here